BeOne Medicines (ONC) Stock: Buy, Sell, or Hold?
ONC - BeOne Medicines Ltd. American Depositary Shares
$382.27
-4.19 (-1.08%)
▼
5d:
+2.19%
30d:
+4.73%
90d:
+17.3%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 05, 2026
12d
Get Alerted When ONC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ONC shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ONC shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$508.54
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$315.76
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ONC is currently trading at $382.27, which is considered extended relative to its 30-day fair value range of $351.44 to $372.55. The stock's valuation (Forward PE: 36.6) is in line with its historical norms (36.8). Remarkably, the market is currently pricing in an annual earnings decline of 0.2% over the next few years. This pessimistic expectation contrasts with the company's recent 166.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ONC is in a strong uptrend. The price is approaching resistance at $388.66. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ONC scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $436.46 (+14.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ONC is in a strong uptrend. The price is approaching resistance at $388.66. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ONC scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $436.46 (+14.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$351.44 -
$372.55
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
26.2%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (5/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($436.46)
- WARNING: Composite score 39/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$351.44 -
$372.55
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$344.94
Resistance Level
$388.66
Current Trend
Strong Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
36.60
Wall Street Target
$436.46
(+14.2%)
Revenue Growth (YoY)
29.6%
Earnings Growth (YoY)
166.7%
Profit Margin
10.7%
Valuation Discount vs History
-0.2% cheaper
PE vs Historical
36.6 vs 36.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.2%
(market-implied from PE analysis)
1-Year Target
$381.51
(0%)
2-Year Target
$380.74
(0%)
3-Year Target
$379.98
(-1%)
3-Yr Target (if PE normalizes)
(PE: 37→37)
$382.10
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 36.6, Growth: 36.7%)
$976.67
(+156%)
Base:
(SPY PE: 19.9, Growth: 36.7%)
$530.02
(+39%)
Bear:
(PE: 16.9, Growth: 36.7%)
$450.52
(+18%)
📈
Valuation based on Current Earnings
Forward PE: 35.21 | Forward EPS (Implied): $10.86
Bull Case
$461.59
(+21%)
Analyst growth 15.0%, PE expands to 37.0
Base Case
$382.27
(0%)
Market implied 0.0%, PE stable at 35.2
Bear Case
$292.44
(-24%)
Severe decline -15.0%, PE contracts to 31.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 36.6 to 36.8
Stabilization Target:
$384.40
(+0.6%)
PE Expansion Potential:
+0.6%
Share & Embed Analysis
Last updated: October 23, 2026 8:15 AM ET
Data refreshes hourly during market hours. Next update: 9:15 AM
Data refreshes hourly during market hours. Next update: 9:15 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ONC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$571 | 49 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 52 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 61 BUY |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$686 | 62 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
23 analysts |
$86 | 66 BUY |